Coronavirus
Drug Safety Update
November 2023: Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
NICE Guidance
NG191: COVID-19 rapid guideline: managing COVID-19.
TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19, March 2023
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19, May 2024 (Please note tixagevimab plus cilgavimab is not recommended)
TA1056: Molnupiravir for treating COVID-19, April 2025
COVID-19 Treatments for Non-Hospitalised High-Risk Adults (CMDU)
Antiviral treatments are available for eligible non-hospitalised patients with COVID-19 via the Kent & Medway COVID Medicines Delivery Unit (CMDU) based at Maidstone and Tunbridge Wells hospital.
Referrals can be made by a healthcare provider or self-referral. Please complete the below Kent & Medway CMDU Treatment Referral Form in full and email to mtw-tr.covidtxreferral@nhs.net.
For the treatment of COVID-19 in line with DHSC defined eligibility criteria.
Hospitalised patients: supply is via the treating hospital in accordance with local inpatient COVID-19 treatment pathways.
Non-hospitalised patients: supply is restricted to the COVID-19 Medicines Delivery Unit (CMDU) based at Maidstone and Tunbridge Wells Hospital. Referrals must be made via email to: mtw-tr.covidtxreferral@nhs.net.
| Pack |
|---|
| 30 tablets |
For the treatment of COVID-19 in line with DHSC defined eligibility criteria.
Hospitalised patients: supply is via the treating hospital in accordance with local inpatient COVID-19 treatment pathways.
Non-hospitalised patients: supply is restricted to the COVID-19 Medicines Delivery Unit (CMDU) based at Maidstone and Tunbridge Wells Hospital. Referrals must be made via email to: mtw-tr.covidtxreferral@nhs.net.
| Pack |
|---|
| 40 capsule |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary